Is difelikefalin legal to use in all EU countries?

Yes. The EMA's centralised approval in December 2021 makes difelikefalin legally available and approved across all EU member states, the EEA, and associated territories. However, reimbursement (whether your health system covers the cost) varies by country. Always check with your national health authority or dialysis centre for access details in your specific country.

Can I buy difelikefalin online or from a pharmacy without a prescription?

No. Difelikefalin is a prescription-only medicine in the EU and must be prescribed by a nephrologist or dialysis physician. It is also an intravenous injection, so it can only be administered by trained healthcare professionals at a dialysis centre or hospital. Purchasing it without a prescription or from unauthorised sources would be illegal.

Is difelikefalin a controlled substance in the EU?

No. Despite being an opioid-like molecule, difelikefalin's unique all-D-amino acid structure prevents it from crossing the blood–brain barrier, eliminating the abuse and addiction risks of traditional opioids. The EMA does not classify it as a controlled substance, making it easier to prescribe and distribute through standard pharmaceutical channels.

What if my country doesn't reimburse difelikefalin?

Reimbursement decisions are made by individual EU member states. If difelikefalin is not covered by your national health system, you may be able to appeal or discuss alternative funding options with your dialysis centre. Some hospitals may have special access schemes or patient support programmes. Contact your nephrologist or national renal patient association for guidance.

Are there any legal restrictions on who can receive difelikefalin in the EU?

Difelikefalin is approved specifically for moderate-to-severe uraemic pruritus in adult haemodialysis patients. Your nephrologist will determine eligibility based on clinical criteria, kidney function, and itch severity. There are no legal age limits beyond the "adult" designation, but prescribing is restricted to appropriate clinical use as defined in the EMA-approved indication.

Difelikefalin Legal Status in the EU: EMA Approval & Availability

Difelikefalin, marketed as Korsuva, is a fully approved and legally available medication in the European Union. The European Medicines Agency (EMA) granted marketing authorisation in 2021, making it the first and only targeted treatment for uraemic pruritus—the severe itching that affects people undergoing dialysis for chronic kidney disease. In the EU, it's classified as a prescription-only medicine and is administered intravenously by healthcare professionals during dialysis sessions. This approval followed successful Phase III trials (KALM-1 and KALM-2) that demonstrated meaningful itch relief in approximately 50% of patients, compared to 31–42% on placebo. Unlike traditional opioids, difelikefalin's unique chemical structure prevents it from crossing the blood–brain barrier, avoiding sedation and addiction risk.

Difelikefalin's EMA Approval Status

Difelikefalin received European Medicines Agency (EMA) marketing authorisation in December 2021 under the centralised procedure—the gold standard for regulatory approval across all EU member states. This means the medicine is legally approved and available throughout the European Union, European Economic Area (EEA), and associated territories.

The approved indication is specifically: treatment of moderate-to-severe uraemic pruritus in adult haemodialysis patients. The drug is supplied as an intravenous injection and is administered by healthcare professionals at the end of each dialysis session. Because difelikefalin is a prescription-only medicine in the EU, patients cannot purchase it over-the-counter; it must be prescribed by a nephrologist or dialysis centre physician.

Regulatory History in the EU

Difelikefalin's path to EU approval began with two pivotal Phase III randomised controlled trials:

KALM-1 and KALM-2 Trials

Both trials enrolled haemodialysis patients with moderate-to-severe uraemic pruritus. The results showed:

Approximately 50% of patients on difelikefalin achieved a clinically meaningful reduction in itch severity (≥3-point reduction on the Numerical Rating Scale)
31–42% on placebo achieved the same endpoint
The effect emerged within the first week of treatment and was sustained over the trial period
No significant abuse potential or central nervous system side effects were observed

These trials—totalling 23 clinical studies across the development programme—provided the evidence base for EMA submission. The EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed the data under the centralised procedure and issued a positive opinion, leading to the European Commission's formal approval.

Why the Centralised Procedure Matters

The centralised procedure ensures uniform approval across all EU countries. Once authorised, difelikefalin doesn't need separate national approvals in Germany, France, Spain, Italy, or any other member state—one EMA decision covers them all. This contrasts with the decentralised procedure, where medicines are approved country by country.

Mechanism & Why It's Uniquely Safe for EU Regulation

Difelikefalin's legal and regulatory profile in the EU is strengthened by its innovative chemistry. The drug is built from all-D-amino acids—mirror-image versions of natural amino acids. This unusual structure is deliberate: it prevents the molecule from crossing the blood–brain barrier, meaning it acts on opioid receptors in the body (particularly in the skin and gut) without reaching the central nervous system.

For EU regulators, this was a critical safety feature. Traditional opioids carry strict scheduling because they cause sedation, euphoria, and addiction risk. Difelikefalin avoids these harms by design. Consequently, it is not a controlled substance in the EU and does not fall under the Schengen Information System (SIS) or EU narcotics scheduling. This makes it easier to distribute, prescribe, and handle in clinical settings.

The EMA recognised this distinction, and difelikefalin's regulatory classification reflects low abuse potential and low risk of diversion.

Current Legal Status & Enforcement

Where It's Available

Difelikefalin is legally dispensed through:

Dialysis centres: Most commonly, as in-centre administration during haemodialysis
Hospital pharmacies: For patients undergoing dialysis in hospital settings
Specialist renal pharmacies: In some EU countries with centralised pharmacy distribution

It is not available in community pharmacies for retail sale. Patients cannot order it from online pharmacies or purchase it without a valid prescription from a nephrologist or dialysis physician.

Pricing & Reimbursement

EU member states negotiate their own reimbursement and pricing agreements. Some countries have secured favorable health technology assessment (HTA) agreements through mechanisms like:

Managed entry agreements: Outcomes-based contracts where payers only reimburse if itch relief thresholds are met
National pricing negotiations: Individual EU countries may negotiate discounts with the manufacturer

Access varies by country. For example, some northern European health systems may have rapid reimbursement, while others conduct formal HTA reviews that can delay coverage. The EMA approval guarantees legal availability; national reimbursement determines practical access.

Enforcement & Supply Chain Control

The EMA and national regulatory authorities (like the UK's MHRA, Germany's BfArM, or France's ANSM) monitor supply and ensure Korsuva is only distributed through legitimate pharmaceutical channels. Counterfeit or unauthorised versions would be illegal. Because difelikefalin is a prescription-only injectable, the supply chain is tightly controlled—there is minimal risk of grey-market diversion.

What Patients in the EU Should Know

Legal Rights

Access: If prescribed by your nephrologist, you have a legal right to receive difelikefalin under EU law. If your country has reimbursement coverage, it should be provided at little or no cost to the patient.
Approval & Safety: The EMA has vetted the drug's safety and efficacy. You can access the full EMA assessment report (EPAR) publicly on the EMA website.
No Risk of Legal Consequences: Using difelikefalin as prescribed carries no legal risk. It is not a controlled substance.

Limitations & Practical Considerations

Prescription-Only: You cannot purchase difelikefalin without a prescription or self-administer it at home. It must be given intravenously by trained staff at your dialysis centre.
Efficacy is Not Guaranteed: Approximately 50% of patients see meaningful relief; others may see partial benefit or none. Your nephrologist can assess your response and adjust treatment.
Reimbursement Varies: Some EU countries may not yet cover difelikefalin, or may require prior authorisation or appeal. Check with your national health authority or dialysis centre.
Oral Development: A difelikefalin oral formulation is in Phase III trials for patients with chronic kidney disease not yet on dialysis. Once approved, this could expand access significantly.

Comparator Status: Related Treatments

Before difelikefalin's approval, uraemic pruritus had no targeted approved treatment in the EU. Patients relied on:

Emollients & topical agents: Skin creams (not systematically effective)
Antihistamines: Off-label, with modest benefit
Gabapentin & pregabalin: Off-label nerve agents (regulatory focus in other indications)
Phototherapy & dialysis optimisation: Non-pharmacological approaches

Difelikefalin (Korsuva) filled a genuine unmet need and is now the only EMA-approved, targeted treatment for this indication. Other agents under investigation globally (such as naloxone analogues or kappa-opioid agonists) have not yet reached EU approval.

Regulatory Pathway: How Difelikefalin Got Here

Preclinical Work: Scientists designed all-D-amino acid structure to prevent CNS penetration
IND & Phase I–II: Early safety and dose-finding studies
Phase III (KALM-1 & KALM-2): Large randomised trials in haemodialysis patients (2019–2020)
EMA Submission: Dossier filed under centralised procedure
CHMP Review: Scientific assessment and risk–benefit evaluation
EMA Approval: December 2021, valid across all EU member states
Post-Marketing Surveillance: Ongoing monitoring for adverse events and efficacy

This entire process took approximately 12–15 years from initial research to EMA approval, a typical timeline for innovative medicines.

Key Takeaways for EU Patients and Caregivers

Difelikefalin is legal and approved throughout the EU via centralised EMA authorisation.
It is prescription-only and administered in dialysis centres by healthcare professionals.
It is not a controlled substance and carries no abuse risk or legal jeopardy for patients.
Efficacy varies: about half of patients see meaningful itch relief; your nephrologist can help assess whether it's right for you.
Reimbursement depends on your country and may require prior authorisation.
An oral version is in development and could expand access beyond haemodialysis patients.
For the first time, uraemic pruritus has a targeted, evidence-based treatment approved by European regulators.

If you're considering difelikefalin, speak with your nephrologist about eligibility, likely benefit, and reimbursement in your country. The EMA's approval is your assurance that the medicine has met rigorous safety and efficacy standards.

Glossary: Key Terms

Centralised Procedure: The regulatory pathway where a single EMA decision grants approval across all EU member states.

Uraemic Pruritus: Severe itching caused by the buildup of uremic toxins in patients with kidney disease, particularly those on dialysis.

Blood–Brain Barrier: The selective membrane that prevents most large or polar molecules from entering the brain.

All-D-Amino Acids: Mirror-image forms of amino acids that prevent enzymatic degradation and CNS penetration.

Difelikefalin's Legal Status in the EU: What You Need to Know